McDermott Will & Emery, a leading international law firm, has made significant additions to its healthcare practice group, as reported by Bloomberg Law. The firm announced on Tuesday the addition of a five-lawyer team to expand their healthcare portfolio, led by partners James Ravitz and Paul Gadiock.
James Ravitz, an established expert in the area of life sciences and healthcare regulations, will be assisting the firm’s clients with regulatory counsel, enforcement defense, litigation and compliance guidance. Known for his strategic approach to healthcare law, Ravitz brings added depth to the practice group.
Paul Gadiock, a renowned counsel to life sciences, healthcare, and other FDA-regulated companies, will be based out of McDermott’s San Francisco office. Known for his expertise throughout the product lifecycle, Gadiock is a former member of senior leadership at the FDA’s Center for Devices and Radiological Health, bringing valuable regulatory insight to the team.
Both Ravitz and Gadiock, along with several other healthcare and FDA lawyers, have made their transition from Wilson Sonsini, adding further depth to McDermott’s healthcare practice group.
This move evidences McDermott’s commitment to bolstering its healthcare and life sciences practice, by adding individuals with extensive experience to the group. It will be interesting to observe how these additions impact the firm’s offerings and standing in the competitive legal sector.
The information was originally reported by McDermott Will & Emery on Tuesday.